Table 1.
Demographic features and platelet count of subjects enrolled in this study.
Figure 1.
Anti-GPIIb/IIIa and anti-GPIb antibody-producing B cells in the circulation of patients with various thrombocytopenic conditions and healthy controls.
Cut-off values for anti-GPIIb/IIIa and anti-GPIb antibody-producing B cells were 2.0 and 2.4 per 105 PBMCs, respectively. Bars indicate the mean, and asterisks indicate statistical significance (P<0.05).
Figure 2.
Correlations between circulating anti-GPIb and anti-GPIIb/IIIa antibody-producing B cells in patients with primary ITP, SLE, liver cirrhosis, and post-HSCT.
Table 2.
Positive frequencies of circulating anti-GPIIb/IIIa and anti-GPIb antibody-producing B cells, and their combination in patients with primary ITP, various thrombocytopenic conditions, and healthy controls.
Table 3.
Clinical findings in patients with primary ITP, stratified by the presence or absence of circulating anti-GPIb or anti-GPIIb/IIIa antibody-producing B cells.